Saturday 17 October 2026 Export KRSA’s income statement to Excel — free account

Korsana Biosciences, Inc.

In the quarter to June 2026, revenue fell 43.2%, EPS fell 272.7% and free cash flow fell 184.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

32.38 1.27 −3.77%

Follow KRSA

Alert me

Market cap: $1.5B
P/E: 0.0×
Fwd P/E: −2.5×
Dividend yield: —
F-score: n/a
Altman Z: −36.29
Beneish M: −1.95
Dividend safety: n/a

Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 1,530.00

Revenue 2.07

Net Income (6.71)

Free Cash Flow (4.52)

Net Debt (1.39)

Current Ratio 0.82

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (2.48)

P/S ratio 9.48

P/B ratio 3.87

Past 5Y EPS Growth —

This Y EPS Growth 10.45%

Next Y EPS Growth 17.50%

Next Y revenue growth (46.96%)

Next 5Y EPS Growth 59.52%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 42.53%

10-year low 10-year high

P/B against its own 10 years 99.18%

10-year low 10-year high

EV/Sales against its own 10 years 68.03%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	8	3	3	1
Receivables	—	1	1	—
Inventory	—	—	—	—
Other	0	0	0	0
	8	4	5	2

	2023	2024	2025	Q'26
Payables	1	0	1	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	2	1	1	2

Compound Annual Growth %

	10y	5y	3y
Sales	—	(14.38%)	(19.27%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(31.33%)	(4.56%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	0	0	1	1	2
’24	—	—	0	2	2
’22	1	0	—	—	0
’21	0	3	0	1	4
’20	1	1	0	0	2

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(1)	(1)	0	(2)	(3)
’24	(2)	(1)	(2)	0	(4)
’23	(6)	(7)	(7)	(2)	(21)
’22	(13)	(11)	(10)	(7)	(41)
’21	(14)	(6)	(8)	(9)	(37)
’20	(29)	(14)	(15)	(14)	(72)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(1)	(1)	0	(2)	(3)
’24	(2)	(1)	(2)	0	(4)
’23	(6)	(7)	(7)	(2)	(21)
’22	(13)	(11)	(10)	(7)	(41)
’21	(13)	(6)	(8)	(9)	(35)
’20	(31)	(14)	(15)	(13)	(72)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(5.32)	(2.87)	—	—	—
’25	(3.92)	(0.77)	(2.10)	(1.33)	(7.77)
’24	(4.34)	(3.71)	(2.03)	1.54	(8.47)
’23	(22.39)	(12.81)	19.03	0.43	(15.75)
’22	(41.99)	(43.39)	(33.59)	(22.39)	(141.36)
’21	(55.02)	(62.98)	(36.39)	(33.59)	(184.74)
’20	(102.17)	(97.97)	(82.58)	(76.98)	(358.29)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	236.60	290.78	208.60	49.00	12.25	8.89	8.12	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	3,199.00	1,254.40	966.00	264.60	133.98	66.29	43.75
People
People	Employees	—	—	143	94	94	32	16	1	1	1
	Revenue/emp, $m	—	—	0.00	0.05	0.02	0.12	0.02	0.00	2.00	2.07
Income, $m
Income, $m	Revenue	—	—	—	5	2	4	0	—	2	2
	Gross margin, %	0.00	0.00	0.00	100.00	100.00	100.00	100.00	—	100.00	100.00
	EBT	(64)	(94)	(115)	(123)	(78)	(52)	(18)	(13)	(3)	(4)
	EBT margin, %	0.00	0.00	0.00	(2,729.27)	(3,388.59)	(1,310.17)	(6,143.43)	0.00	(152.85)	(170.11)
	Net income	(64)	(94)	(115)	(123)	(78)	(52)	(44)	(5)	(3)	(4)
	Depreciation	2	2	2	3	2	0	0	—	—	—
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	23.04	10.57	14.09	0.96	0.00	5.56	4.56
	Earnings	(2.32)	(3.43)	(589.13)	(628.41)	(358.29)	(184.74)	(141.36)	(15.75)	(8.47)	(7.77)
	Cash flow	(1.82)	(2.96)	(498.48)	(522.57)	(333.75)	(130.56)	(130.79)	(63.59)	(12.04)	(7.29)
	Capex	0.00	(0.05)	(17.58)	(34.33)	0.08	5.21	0.00	0.00	0.00	0.00
	Free cash flow	(1.82)	(3.02)	(516.06)	(556.90)	(333.66)	(125.35)	(130.79)	(63.59)	(12.04)	(7.29)
	Book value	(0.25)	(0.31)	(53.40)	499.64	273.91	172.49	33.66	33.79	24.60	19.98
	Shares, m	27	27	0	0	0	0	0	0	0	0
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	—	0.00	0.00
	P/S	—	—	—	0.00	40.53	17.09	35.13	—	5.11	1.95
	P/B	—	—	—	0.76	1.56	1.40	2.79	—	0.92	0.44
	EV/Sales	—	—	—	0.00	16.84	3.40	18.99	—	3.08	0.39
	EV/FCF	—	—	—	0.19	(0.53)	(0.38)	(0.40)	—	(1.70)	(0.43)
Cash, $m
Cash, $m	Operating cash flow	(50)	(81)	(98)	(102)	(72)	(37)	(41)	(21)	(4)	(3)
	Capex	(1)	(1)	(3)	(7)	0	1	—	—	—	—
	Free cash flow	(50)	(83)	(101)	(109)	(72)	(35)	(41)	(21)	(4)	(3)
Balance, $m
Balance, $m	Working capital	(10)	(13)	(17)	83	42	44	7	6	4	4
	Total debt	—	—	—	74	46	—	—	—	—	—
	Net debt	—	—	—	(95)	(54)	(54)	(13)	(8)	(3)	(3)
	Shareholders’ equity	(7)	(9)	(10)	98	59	48	10	11	9	9
Returns, %
Returns, %	ROA	(1,360.17)	(2,010.10)	(1,790.88)	(126.89)	(51.55)	(59.12)	(113.88)	(33.47)	(26.64)	(36.07)
	ROIC	0.00	0.00	0.00	(2,757.52)	(996.29)	0.00	0.00	(217.77)	(40.36)	(53.18)
	ROE	829.25	1,225.50	1,212.41	(281.86)	(98.97)	(95.87)	(150.19)	(48.42)	(30.36)	(39.34)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NTLA Intellia Therapeutics, Inc.	$1.6B	— (loss-making)	— (loss-making)	−46.23% (below 0%: shrinking)	n/m	+15.05% (above 0%: growing)	100.00%	(1,472.25%)	Compare
STOK Stoke Therapeutics, Inc.	$1.6B	— (loss-making)	— (loss-making)	−32.51% (below 0%: shrinking)	n/m	−128.97% (below 0%: shrinking)	100.00%	(701.65%)	Compare
GPCR Structure Therapeutics Inc. Sponsored ADR	$1.6B	— (loss-making)	—	—	n/m	−119.15% (below 0%: shrinking)	0.00%	0.00%	Compare
QURE uniQure N.V.	$1.6B	— (loss-making)	— (loss-making)	+11.00% (above 0%: growing)	n/m	+27.66% (above 0%: growing)	94.01%	(893.73%)	Compare
KRSA Korsana Biosciences, Inc.	$1.5B	— (loss-making)	— (loss-making)	−43.24% (below 0%: shrinking)	n/m	−184.69% (below 0%: shrinking)	100.00%	0.00%
MAZE Maze Therapeutics, Inc.	$1.5B	— (loss-making)	—	—	n/m	+50.21% (above 0%: growing)	100.00%	0.00%	Compare
ABSI Absci Corporation	$1.5B	— (loss-making)	— (loss-making)	−46.37% (below 0%: shrinking)	n/m	−71.74% (below 0%: shrinking)	100.00%	(10,741.51%)	Compare
IMCR Immunocore Holdings PLC Sponsored ADR	$1.5B	— (loss-making)	208×	+18.34% (above 0%: growing)	n/m	−40.74% (below 0%: shrinking)	99.06%	(2.58%)	Compare
RARE Ultragenyx Pharmaceutical Inc.	$1.5B	— (loss-making)	— (loss-making)	+28.14% (above 0%: growing)	n/m	+12.50% (above 0%: growing)	84.11%	(35.05%)	Compare
Median of peers	$1.5B	—	—	−10.75%	—	−14.12%	99.53%	(368.35%)

All 614 Biotechnology stocks →